Newly Opened Clinical Trial: The BEACON Study (Breast Cancer Outcomes with NKTR-102)

The Weill Cornell Breast Center has recently opened a new clinical trial for women with locally recurrent or metastatic breast cancer that was previously treated with anthracycline, a taxane, and capecitabine. The study sponsor is Nektar Therapeutics. The principal investigator at Weill Cornell is Dr. Tessa Cigler. For more information about the study, please call Marta Cobham, RN at (212) 821-0780 or e-mail Marta at

Study Details

The purpose of the study is to test how well women with breast cancer respond to treatment with the experimental drug NKTR-102, compared to standard treatments for breast cancer. The study will also look at the side effects of the study drug and examine how long NKTR-102 stays in a patient’s blood.

Treatment Plan

Study participants will be randomly assigned to one of two study arms:

  • Arm A: participants will receive NKTR-102 via infusion on Day 1 of each 21 day cycle.
  • Arm B: participants will receive one of seven standard of care treatment options available at the study center. The choice of treatment in Arm B will be made after discussions with your doctor. Depending on which drug is chosen by you and your doctor, cycles in Arm B will be either 21 days or 28 days.

The study will take about 38 months to complete. The amount of time on study depends on how well a participant responds to study treatment.

Key Eligibility

  • Women age 18 and older
  • Diagnosed with breast cancer
  • Locally recurrent or metastatic disease
  • Prior therapy must have included anthracycline, a taxane, and Xeloda; must have received a minimum of 2 and maximum of 5 prior cytoxic chemotherapy regimens
  • Detailed eligibility reviewed when you contact the study team

Leave a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s